Market open
United Therapeutics/$UTHR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Ticker
$UTHR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,305
Website
UTHR Metrics
BasicAdvanced
$14B
12.39
$24.64
0.64
-
Price and volume
Market cap
$14B
Beta
0.64
52-week high
$403.35
52-week low
$221.53
Average daily volume
556K
Financial strength
Current ratio
5.248
Quick ratio
4.805
Long term debt to equity
0.504
Total debt to equity
5.255
Interest coverage (TTM)
33.71%
Management effectiveness
Return on assets (TTM)
12.44%
Return on equity (TTM)
19.23%
Valuation
Price to earnings (TTM)
12.394
Price to revenue (TTM)
4.797
Price to book
2.12
Price to tangible book (TTM)
2.16
Price to free cash flow (TTM)
12.774
Growth
Revenue change (TTM)
23.63%
Earnings per share change (TTM)
24.38%
3-year revenue growth (CAGR)
19.52%
3-year earnings per share growth (CAGR)
34.80%
What the Analysts think about UTHR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
UTHR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
UTHR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
UTHR News
AllArticlesVideos
United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
Business Wire·2 weeks ago
United Therapeutics: A Unique Business With High Margins And Expansion Potential
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for United Therapeutics stock?
United Therapeutics (UTHR) has a market cap of $14B as of March 14, 2025.
What is the P/E ratio for United Therapeutics stock?
The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 12.39 as of March 14, 2025.
Does United Therapeutics stock pay dividends?
No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next United Therapeutics dividend payment date?
United Therapeutics (UTHR) stock does not pay dividends to its shareholders.
What is the beta indicator for United Therapeutics?
United Therapeutics (UTHR) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.